Cargando…

Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities

SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xiaodong, Jiang, Wenguo, Zhang, He, Lu, XiXi, Li, Libo, Liu, Wenjun, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631518/
https://www.ncbi.nlm.nih.gov/pubmed/34858383
http://dx.doi.org/10.3389/fmicb.2021.789374
_version_ 1784607579193737216
author Tian, Xiaodong
Jiang, Wenguo
Zhang, He
Lu, XiXi
Li, Libo
Liu, Wenjun
Li, Jing
author_facet Tian, Xiaodong
Jiang, Wenguo
Zhang, He
Lu, XiXi
Li, Libo
Liu, Wenjun
Li, Jing
author_sort Tian, Xiaodong
collection PubMed
description SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In this study, we used enzyme-linked immunosorbent assays (ELISA) and neutralization assay with purified SARS-CoV-2S and N proteins to study the antibody responses of 156 individuals with natural asymptomatic infection. We found robust antibody responses to SARS-CoV-2 in 156 patients from 6 to 12 months. Although the antibody responses gradually decreased, S-IgG was more stable than N-IgG. S-IgG was still detected in 79% of naturally infected individuals after 12 months of infection. Moderate to potent neutralization activities were also observed in 98.74% of patients 6 months after infection. However, this proportion decreased at 8-month (46.15%) and 10-month (39.11%) after infection, respectively. Only 23.72% of patients displayed potent neutralization activity at 12 months. This study strongly supports the long-term presence of antibodies against SARS-CoV-2 in individuals with natural asymptomatic infection, although the magnitude of the antibody responses started to cripple 6 months after infection.
format Online
Article
Text
id pubmed-8631518
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86315182021-12-01 Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities Tian, Xiaodong Jiang, Wenguo Zhang, He Lu, XiXi Li, Libo Liu, Wenjun Li, Jing Front Microbiol Microbiology SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In this study, we used enzyme-linked immunosorbent assays (ELISA) and neutralization assay with purified SARS-CoV-2S and N proteins to study the antibody responses of 156 individuals with natural asymptomatic infection. We found robust antibody responses to SARS-CoV-2 in 156 patients from 6 to 12 months. Although the antibody responses gradually decreased, S-IgG was more stable than N-IgG. S-IgG was still detected in 79% of naturally infected individuals after 12 months of infection. Moderate to potent neutralization activities were also observed in 98.74% of patients 6 months after infection. However, this proportion decreased at 8-month (46.15%) and 10-month (39.11%) after infection, respectively. Only 23.72% of patients displayed potent neutralization activity at 12 months. This study strongly supports the long-term presence of antibodies against SARS-CoV-2 in individuals with natural asymptomatic infection, although the magnitude of the antibody responses started to cripple 6 months after infection. Frontiers Media S.A. 2021-11-10 /pmc/articles/PMC8631518/ /pubmed/34858383 http://dx.doi.org/10.3389/fmicb.2021.789374 Text en Copyright © 2021 Tian, Jiang, Zhang, Lu, Li, Liu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Tian, Xiaodong
Jiang, Wenguo
Zhang, He
Lu, XiXi
Li, Libo
Liu, Wenjun
Li, Jing
Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_full Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_fullStr Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_full_unstemmed Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_short Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_sort persistence of the sars-cov-2 antibody response in asymptomatic patients in correctional facilities
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631518/
https://www.ncbi.nlm.nih.gov/pubmed/34858383
http://dx.doi.org/10.3389/fmicb.2021.789374
work_keys_str_mv AT tianxiaodong persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
AT jiangwenguo persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
AT zhanghe persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
AT luxixi persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
AT lilibo persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
AT liuwenjun persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
AT lijing persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities